12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Debio 1143: Phase I started

Debiopharm began a Phase I trial to evaluate Debio 1143 plus carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), platinum-refractory ovarian cancer or...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >